 | BRIEF-BeiGene Presents Interim Analysis Results Of Rationale 303 Trial Of Tislelizumab In Second- Or Third-Line Non-Small Cell Lung Cancer At Aacr Annual Meeting msn.com - April 13 at 12:08 PM |
 | BeiGene Reports Phase 1b Data For Sitravatinib And Tislelizumab Combination - Nasdaq nasdaq.com - April 12 at 10:44 PM |
 | BeiGene Presents Interim Analysis Results of RATIONALE 303 Trial of Tislelizumab in Second- or Third-Line Non-Small Cell Lung Cancer at the AACR Annual Meeting 2021 - Business Wire businesswire.com - April 12 at 5:43 PM |
 | BeiGene Presents Interim Analysis Results of RATIONALE 303 Trial of Tislelizumab in Second- or Third-Line Non-Small Cell Lung Cancer at the AACR Annual Meeting 2021 finance.yahoo.com - April 12 at 5:43 PM |
 | BeiGene Reports Phase 1b Data For Sitravatinib And Tislelizumab Combination finance.yahoo.com - April 12 at 12:43 PM |
 | BeiGene Presents Clinical Data on Sitravatinib in Combination with Tislelizumab at the AACR Annual Meeting 2021 - Business Wire businesswire.com - April 11 at 7:25 PM |
 | BeiGene (BGNE) Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress Did Not Meet Co-primary Efficacy Endpoints - StreetInsider.com streetinsider.com - April 9 at 5:51 AM |
 | BeiGene Provides Update on Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress - Yahoo Finance finance.yahoo.com - April 8 at 7:32 AM |
|
 | BeiGene Launches BRUKINSA® (Zanubrutinib) in Canada for Patients with Waldenström’s Macroglobulinemia finance.yahoo.com - April 8 at 7:32 AM |
 | BeiGene Provides Update on Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress finance.yahoo.com - April 8 at 7:32 AM |
 | BeiGene Announces First Commercial Manufacturing Approval for Its State-of-the-Art Biologics Facility in Guangzhou, China finance.yahoo.com - April 7 at 7:52 PM |
 | BeiGene (NASDAQ:BGNE) Trading Down 4.2% Following Insider Selling americanbankingnews.com - April 1 at 12:22 PM |
 | BeiGene, Ltd. (NASDAQ:BGNE) CMO Sells $486,000.00 in Stock americanbankingnews.com - March 31 at 7:48 PM |
 | Stocks Showing Improving Market Leadership: Beigene Earns 82 RS Rating - Investor's Business Daily investors.com - March 30 at 3:37 PM |
 | BeiGene (BGNE) Names Julia Wang as New CFO - StreetInsider.com streetinsider.com - March 30 at 3:37 PM |
 | BeiGene names Julia Wang CFO - Seeking Alpha seekingalpha.com - March 30 at 3:37 PM |
 | BeiGene Announces New Chief Financial Officer, Julia Wang - Business Wire businesswire.com - March 30 at 3:37 PM |
 | BeiGene Announces New Chief Financial Officer, Julia Wang finance.yahoo.com - March 30 at 10:36 AM |
 | Personalis Announces Collaboration with MapKure to Use Personalis' NeXT Platform™ for Clinical Trials and Companion Diagnostic Development - Business Wire businesswire.com - March 29 at 8:08 PM |
 | Hutchison China, BeiGene Start Testing Surufatinib/Tislelizumab Combo In Solid Tumor Study - Benzinga benzinga.com - March 25 at 5:20 PM |
 | Chi-Med, BeiGene launches mid-stage combo study in solid tumors - Seeking Alpha seekingalpha.com - March 24 at 5:52 AM |
 | Beigene Clears Technical Benchmark, Hitting 80-Plus RS Rating - Investor's Business Daily investors.com - March 22 at 1:35 PM |
 | BeiGene (BGNE) Doses First Patient in Phase 1 Trial of BGB-15025 - StreetInsider.com streetinsider.com - March 11 at 9:23 AM |
 | BeiGene Announces Presentation of Clinical and Preclinical Data at the AACR Annual Meeting 2021 - Yahoo Finance finance.yahoo.com - March 11 at 12:04 AM |
 | BeiGene Announces Presentation of Clinical and Preclinical Data at the AACR Annual Meeting 2021 - Business Wire businesswire.com - March 10 at 7:04 PM |
 | BeiGene Announces Presentation of Clinical and Preclinical Data at the AACR Annual Meeting 2021 finance.yahoo.com - March 10 at 7:04 PM |
|
 | Dosing underway in BeiGene's study of HPK1 inhibitor BGB-15025 - Seeking Alpha seekingalpha.com - March 10 at 2:03 PM |
 | BeiGene Initiates Phase 1 Clinical Trial for HPK1 Inhibitor BGB-15025 - Business Wire businesswire.com - March 10 at 9:02 AM |
 | BeiGene Initiates Phase 1 Clinical Trial for HPK1 Inhibitor BGB-15025 finance.yahoo.com - March 10 at 9:02 AM |
 | BeiGene's tislelizumab lung cancer sBLA accepted in China - Seeking Alpha seekingalpha.com - March 5 at 5:53 PM |
 | BeiGene (BGNE) Announces Acceptance of sBLA in China for Tislelizumab in Second- or Third-line Non-Small Cell Lung Cancer - StreetInsider.com streetinsider.com - March 5 at 12:52 PM |
 | BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Second- or Third-line Non-Small Cell Lung Cancer - Business Wire businesswire.com - March 5 at 12:52 PM |
 | BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Second- or Third-line Non-Small Cell Lung Cancer finance.yahoo.com - March 5 at 12:52 PM |
 | Health Canada Approves BRUKINSA® (Zanubrutinib) for the Treatment of Waldenström’s Macroglobulinemia finance.yahoo.com - March 2 at 9:28 AM |
 | BeiGene downgraded by CLSA after 2020 earnings miss - Seeking Alpha seekingalpha.com - March 1 at 1:36 PM |
 | UPDATE: CLSA Downgrades BeiGene, Ltd. (BGNE) to Underperform (4) - StreetInsider.com streetinsider.com - March 1 at 8:35 AM |
 | Can BeiGene Stock Rebound After A 10% Drop? - Nasdaq nasdaq.com - February 28 at 7:17 PM |
 | BeiGene, Ltd. (NASDAQ:BGNE) Analysts Just Slashed This Year's Revenue Estimates By 33% - Yahoo Finance Australia finance.yahoo.com - February 27 at 8:51 AM |
 | BeiGene, Ltd. (NASDAQ:BGNE) Analysts Just Slashed This Year's Revenue Estimates By 33% finance.yahoo.com - February 27 at 8:51 AM |
 | BeiGene closes - Seeking Alpha seekingalpha.com - February 26 at 5:49 PM |
 | Can BeiGene Stock Rebound After A 10% Drop? forbes.com - February 26 at 12:48 PM |
 | BeiGene Announces Closing of Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab in North America, Europe and Japan - Yahoo Finance finance.yahoo.com - February 26 at 7:48 AM |
 | BeiGene Announces Closing of Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab in North America, Europe and Japan finance.yahoo.com - February 26 at 7:48 AM |
 | Assembly Biosciences Updates Pipeline Strategy, Focusing on Finite and Curative Therapies for Chronic Hepatitis B Virus Infection - StreetInsider.com streetinsider.com - February 26 at 1:19 AM |
 | SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights - StreetInsider.com streetinsider.com - February 25 at 10:17 AM |
 | Form 8-K Zymeworks Inc. For: Feb 24 - StreetInsider.com streetinsider.com - February 25 at 12:54 AM |
 | Leap Therapeutics to Present at Upcoming Virtual Investor Conferences - StreetInsider.com streetinsider.com - February 22 at 7:40 PM |
 | Leap Therapeutics to Present at Upcoming Virtual Investor Conferences - Yahoo Finance finance.yahoo.com - February 22 at 9:39 AM |
 | BeiGene's US Application For BRUKINSA In A Type Of Lymphoma, Accepted For Review - Benzinga benzinga.com - February 18 at 7:55 PM |
 | BeiGene, Ltd. (BGNE) PT Raised to $429 at Cowen - StreetInsider.com streetinsider.com - February 18 at 9:54 AM |